𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities

✍ Scribed by Jessica Plati; Octavian Bucur; Roya Khosravi-Far


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
314 KB
Volume
104
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Apoptosis is a tightly regulated cell suicide program that plays an essential role in the maintenance of tissue homeostasis by eliminating unnecessary or harmful cells. Defects in this native defense mechanism promote malignant transformation and frequently confer chemoresistance to transformed cells. Indeed, the evasion of apoptosis has been recognized as a hallmark of cancer. Given that multiple mechanisms function at many levels to orchestrate the regulation of apoptosis, a multitude of opportunities for apoptotic dysregulation are present within the intricate signaling network of cell. Several of the molecular mechanisms by which cancer cells are protected from apoptosis have been elucidated. These advances have facilitated the development of novel apoptosis‐inducing agents that have demonstrated single‐agent activity against various types of cancers cells and/or sensitized resistant cancer cells to conventional cytotoxic therapies. Herein, we will highlight several of the central modes of apoptotic dysregulation found in cancer. We will also discuss several therapeutic strategies that aim to reestablish the apoptotic response, and thereby eradicate cancer cells, including those that demonstrate resistance to traditional therapies. J. Cell. Biochem. 104: 1124–1149, 2008. Β© 2008 Wiley‐Liss, Inc.


πŸ“œ SIMILAR VOLUMES


Dynamic survivin in head and neck cancer
✍ Burkhard M. Lippert; Shirley K. Knauer; Verena Fetz; Wolf Mann; Roland H. Staube πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 594 KB

## Abstract Although disease management of head and neck squamous cell carcinomas (HNSCC) has improved significantly, therapy resistance leading to tumor recurrence still counteracts improvement of long‐term survival. Consequently, identification of molecular markers that signal increased risk of t